Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:EMBCNASDAQ:IRMDNASDAQ:LUNG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$10.47+2.1%$12.29$7.09▼$21.00$466.83M1.05483,959 shs596,311 shsEMBCEmbecta$9.28-6.5%$11.07$9.25▼$21.48$580.33M1.13490,269 shs691,433 shsIRMDiRadimed$60.71+0.5%$55.39$42.34▼$63.29$767.99M0.9243,815 shs64,019 shsLUNGPulmonx$2.59-1.5%$3.49$2.50▼$9.37$105.88M0.52306,683 shs317,131 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+2.15%+12.70%-7.35%-42.97%+39.60%EMBCEmbecta-6.55%-4.72%-17.58%-24.43%-24.37%IRMDiRadimed+0.51%+3.87%+15.53%+15.84%+41.02%LUNGPulmonx-1.52%-5.82%-16.18%-62.02%-57.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.6672 of 5 stars3.52.00.00.02.62.50.6EMBCEmbecta4.4907 of 5 stars3.21.03.30.02.63.33.8IRMDiRadimed4.6656 of 5 stars2.52.02.54.43.23.31.9LUNGPulmonx3.6829 of 5 stars3.35.00.00.03.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.20112.03% UpsideEMBCEmbecta 2.33Hold$19.33108.33% UpsideIRMDiRadimed 3.00Buy$72.0018.60% UpsideLUNGPulmonx 2.63Moderate Buy$11.53344.98% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, AXGN, IRMD, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M2.55N/AN/A$2.36 per share4.44EMBCEmbecta$1.12B0.48$3.11 per share2.98($12.80) per share-0.73IRMDiRadimed$73.24M10.54$1.59 per share38.17$6.85 per share8.86LUNGPulmonx$83.79M1.24N/AN/A$2.17 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.15N/AN/AN/A-3.68%-7.09%-3.67%8/6/2025 (Estimated)EMBCEmbecta$78.30M$0.9010.313.020.634.89%-19.67%12.27%8/8/2025 (Estimated)IRMDiRadimed$19.23M$1.5539.1730.36N/A26.33%23.28%20.59%7/30/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)Latest LUNG, AXGN, IRMD, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/AEMBCEmbecta$0.606.47%N/A66.67%N/AIRMDiRadimed$0.681.12%N/A43.87%1 YearsLUNGPulmonxN/AN/AN/AN/AN/ALatest LUNG, AXGN, IRMD, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.634.282.65EMBCEmbectaN/A2.481.83IRMDiRadimedN/A8.877.62LUNGPulmonx0.384.974.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%EMBCEmbecta93.83%IRMDiRadimed92.34%LUNGPulmonx91.04%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%EMBCEmbecta0.42%IRMDiRadimed36.80%LUNGPulmonx6.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million44.28 millionOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableLUNG, AXGN, IRMD, and EMBC HeadlinesRecent News About These CompaniesRichard Ferrari Sells 8,000 Shares of Pulmonx Co. (NASDAQ:LUNG) StockJune 14, 2025 | insidertrades.comPulmonx Co. (NASDAQ:LUNG) Director Richard Ferrari Sells 8,000 SharesJune 13, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 11, 2025 | marketbeat.comPulmonx Corporation (LUNG) Stock ForecastsJune 8, 2025 | ca.finance.yahoo.comPulmonx Co. (NASDAQ:LUNG) Director Buys $71,362.26 in StockJune 6, 2025 | insidertrades.comPulmonx Co. (NASDAQ:LUNG) Director Purchases $71,362.26 in StockJune 5, 2025 | marketbeat.comGeoffrey Beran Rose Sells 6,947 Shares of Pulmonx Co. (NASDAQ:LUNG) StockJune 5, 2025 | marketbeat.comMehul Joshi Sells 8,061 Shares of Pulmonx Co. (NASDAQ:LUNG) StockJune 5, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) CEO Sells $31,058.99 in StockJune 5, 2025 | marketbeat.comInsider Selling: Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells 10,457 Shares of StockJune 5, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Insider Sells $21,744.11 in StockJune 5, 2025 | insidertrades.comPulmonx Co. (NASDAQ:LUNG) Sees Large Growth in Short InterestJune 3, 2025 | marketbeat.comPulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceMay 28, 2025 | globenewswire.comWhy Pulmonx Corporation’s (LUNG) Stock Is Down 5.82%May 10, 2025 | aaii.comAIt’s Time to Recognize COPD as a Women’s Health IssueMay 8, 2025 | medscape.comMPulmonx Corporation (NASDAQ:LUNG) Q1 2025 Earnings Call TranscriptMay 6, 2025 | msn.comPulmonx to Present at the Bank of America Securities 2025 Health Care ConferenceMay 1, 2025 | globenewswire.comQ1 2025 Pulmonx Corp Earnings CallMay 1, 2025 | finance.yahoo.comPulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ...May 1, 2025 | uk.finance.yahoo.comPulmonx projects 20% long-term growth amid expanded initiatives and $12B market opportunityApril 30, 2025 | msn.comPulmonx Corporation (LUNG) Q1 2025 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeSouthwest Airlines: Short Interest Plunges—Should You Buy?By Gabriel Osorio-Mazilli | June 17, 2025View Southwest Airlines: Short Interest Plunges—Should You Buy?LUNG, AXGN, IRMD, and EMBC Company DescriptionsAxoGen NASDAQ:AXGN$10.47 +0.22 (+2.15%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$10.18 -0.29 (-2.72%) As of 06/26/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Embecta NASDAQ:EMBC$9.28 -0.65 (-6.55%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$9.39 +0.11 (+1.19%) As of 06/26/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.iRadimed NASDAQ:IRMD$60.71 +0.31 (+0.51%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$60.74 +0.03 (+0.05%) As of 06/26/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Pulmonx NASDAQ:LUNG$2.59 -0.04 (-1.52%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.67 +0.08 (+3.24%) As of 06/26/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
